Summit Creek Advisors LLC Sells 5,907 Shares of LeMaitre Vascular, Inc. $LMAT

Posted by George Bondi on May 21st, 2026

Summit Creek Advisors LLC cut its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 3.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 149,996 shares of the medical instruments supplier’s stock after selling 5,907 shares during the quarter. LeMaitre Vascular comprises about 1.9% of Summit Creek Advisors LLC’s holdings, making the stock its 25th biggest holding. Summit Creek Advisors LLC’s holdings in LeMaitre Vascular were worth $12,165,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. State of Alaska Department of Revenue raised its holdings in LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 147 shares in the last quarter. Johnson Investment Counsel Inc. increased its stake in shares of LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after acquiring an additional 153 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of LeMaitre Vascular by 2.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock worth $630,000 after acquiring an additional 158 shares in the last quarter. Finally, Illinois Municipal Retirement Fund increased its stake in shares of LeMaitre Vascular by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock worth $967,000 after acquiring an additional 171 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $101.43 on Thursday. LeMaitre Vascular, Inc. has a one year low of $78.35 and a one year high of $118.01. The company’s 50-day moving average is $108.94 and its 200 day moving average is $95.20. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of 37.43, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

Analysts Set New Price Targets

LMAT has been the subject of several research reports. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 6th. Citizens Jmp increased their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Roth Mkm reiterated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Wells Fargo & Company increased their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $112.60.

Read Our Latest Stock Report on LeMaitre Vascular

Insider Activity at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This trade represents a 56.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 269,891 shares of company stock worth $28,969,086. 7.40% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

(Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.